Prognostic value of myocardial perfusion-gated SPECT in patients with ischemic cardiomyopathy

Journal of Nuclear Cardiology

Volumn 16, Issue 2, 2009, Pages 212-221

  Candell Riera, Jaume ^a   Romero Farina, Guillermo ^a   Aguadé Bruix, Santiago ^a   Castell Conesa, Joan ^a   León, Gustavo ^a   García Dorado, David ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Gated SPECT; Ischemic cardiomyopathy; Prognosis; Stress test

Indexed keywords

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXERCISE TEST; FEMALE; GATED IMAGING; HEART SCINTISCANNING; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; PROGNOSIS; REST; RISK ASSESSMENT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; AGED; CARDIOMYOPATHY; HEART FAILURE; HEART MUSCLE ISCHEMIA; INCIDENCE; METHODOLOGY; MIDDLE AGED; RISK FACTOR; SCINTISCANNING; SPAIN; SURVIVAL; SURVIVAL RATE;

AGED; CARDIAC-GATED SINGLE-PHOTON EMISSION COMPUTER-ASSISTED TOMOGRAPHY; CARDIOMYOPATHIES; FEMALE; HEART FAILURE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SPAIN; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 67649910845     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12350-008-9042-0     Document Type: Article

References (29)

1. Curtis JP, Sokol SI, Wang Y, Rathore SS, Ko DT, Jadbabaie F, et al. The association of left ventricular ejection, mortality, and cause of death in stable outpatients with heart failure. J Am Coll Cardiol 2003;42:736-42.
2. Gheorghiade M, Cody RJ, Francis CS, McKenna WJ, Young JB, Bonow RO. Current medical therapy for advanced heart failure. Am Heart J 1998;135:S231-48.
3. Moster A, Hoes AW, Bruyne MC, Deckers JW, Linker DT, Hofman A, et al. Prevalence of heart failure and left ventricular dysfunction in the general population. Eur Heart J 1999;20:447-55.
4. Sharir T, Germano G, Kang X, Lewin HC, Miranda R, Cohen I, et al. Prediction of myocardial infarction versus cardiac death by gated myocardial perfusion SPECT: Risk stratification by the amount of stress-induced ischemia and the poststress ejection fraction. J Nucl Med 2001;42:831-7.
5. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002;105:539-42.
6. González JM, Castell-Conesa J, Candell-Riera J, Rossello-Urgell J, Spanish Working Group of Nuclear Cardiology. Relevance of 99m Tc-MIBI rest uptake, ejection fraction and contractile abnormality location in predicting myocardial recovery after revascularization. Nucl Med Commun 2001;22:795-805.
7. Romero-Farina G, Candell-Riera J, Aguadé-Bruix S, Castell-Conesa J, de León G. Analysis of apical remodeling in gated myocardial perfusion SPECT imaging in ischemic cardiomyopathy. J Nucl Cardiol 2008;15:225-31.
8. Germano G, Kiat H, Kavanagh PB, Moriel M, Mazzanti M, Su HT, et al. Automatic quantification of ejection fraction from gated myocardial perfusion SPECT. J Nucl Med 1995;36:2138-47.
9. Candell-Riera J, Santana-Boado C, Bermejo B, Aguade-Bruix S, Bermejo-Fraile B, Soler-Soler J. Dipyridamole administration at the end of an insufficient exercise 99m Tc-MIBI SPECT improves detection of multivessel coronary artery disease in patients with previous myocardial infarction. Am J Cardiol 2000;85:532-5.
10. Gibbons RJ, Miller TD. Tc-99m sestamibi infarct size as a surrogate endpoint. J Nucl Cardiol 2005;12:12-9.
11. Ridker PM, Cook N. Should age and time be eliminated from cardiovascular risk prediction models? Rationale for the creation of a new national risk detection program. Circulation 2005;111:657-8.
12. Vasan RS, D'Agostino RB. Age and time need not and should not be eliminated from the coronary risk prediction models. Circulation 2005;111:542-5.
13. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991;83:778-86.
14. Bittner V. Exercise testing in heart failure. Maximal, submaximal, or both? J Am Coll Cardiol 2003;42:123-5.
15. Myers J, Gullestad L. The role of exercise testing and gas-exchange measurement in the prognosis assessment of patients with heart failure. Curr Opin Cardiol 1998;13:145-55.
16. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997;95:2660-7.
17. Cohen-Solal A, Barnier P, Pessione F, Seknadji P, Logeart D, Laperche T, et al. Comparison of the long-term prognostic value of peak exercise oxygen pulse and peak oxygen uptake in patients with chronic heart failure. Heart 1997;78:572-6.
18. Opasich C, Pinna GD, Bobbio M, Sisti M, Demichelis B, Febo O, et al. Peak exercise oxygen consumption in chronic heart failure: Toward efficient use in the individual patient. J Am Coll Cardiol 1998;31:766-75.
19. Myers J, Gullestad L, Vagelos R, Do D, Bellin D, Ross H, et al. Cardiopulmonary exercise testing and prognosis in severe heart failure: 14 mL/kg/min revisited. Am Heart J 2000;139:78-84.
20. Bruner-La Roca HP, Weilenmann D, Follath F. Oxygen uptake kinetics during level exercise in patients with heart failure: Relation to neurohormones, peak oxygen consumption and clinical findings. Heart 1999;81:121-7.
21. Lauer MS, Snader CE. Using exercise testing to prognosticate patients with heart failure. Which parameter should we measure? Clin Cardiol 2001;19:573-81.
22. Sharir T. Role of regional myocardial dysfunction by gated myocardial perfusion SPECT in the prognostic evaluation of patients with coronary artery disease. J Nucl Cardiol 2005;12:5-7.
23. Kitsiou AN, Srinivasan G, Quyyumi AA, Summers RM, Bacharach SL, Dilsizian V. Stress-induced reversible and mild-to-moderate irreversible thallium defects. Are they equally accurate for predicting recovery of regional left ventricular function after revascularization? Circulation 1998;98:501-8.
24. Meluzín J, Cerney J, Frélich M, Stetka F, Spinarova L, Popelova, et al. Prognosis value of the amount of dysfunctional but viable myocardium in revascularized patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol 1998;32:912-20.
25. Bourque J, Hasselblad V, Velazquez EJ, Borges-Neto S, O'Connor CM. Revascularization in patients with coronary artery disease, left ventricular dysfunction, and viability: A meta-analysis. Am Heart J 2003;146:621-7.
26. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: A meta-analysis. J Am Coll Cardiol 2002;39:1151-8.
27. Senior R, Lahiri A, Kaul S. Effect of revascularization on left ventricular remodeling in patients with heart failure from severe chronic ischemic left ventricular dysfunction. Am J Cardiol 2001;88:624-9.
28. Senior R, Kaul S, Raval U, Lahiri A. Impact of revascularization and myocardial viability determined by nitrate-enhanced Tc-99m sestamibi and Tl-201 imaging on mortality and functional outcome in ischemic cardiomyopathy. J Nucl Cardiol 2002;9:454-62.
29. Cleland JGF, Pennell DJ, Ray SG, Coats AJ, Macfarlane PW, Murray GD, et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): Randomised controlled trial. Lancet 2003;362:14-21.